ALYREF expression in serous ovarian cancer at higher stages (III and IV) was significantly increased compared with expression in cancer at lower stages (I and II) (Figs. 8D and EV8C). The gene discussed is ALYREF; the disease is ovarian serous adenocarcinoma.